Loading
Everything OnCo dates to 1970: 14 entries, 5 landmarks, 4 approvals, 3 technologies and 1 company founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
14 dated entries in OnCo fall in 1970: 5 landmarks, 4 approvals, 3 technologies, 1 company founded and 1 paper.
Of those, 14 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Gastrointestinal adenocarcinoma metastatic to the liver, by continuous regional intra-arterial infusion
Topical: actinic keratosis and superficial basal cell carcinoma
Inoperable adrenocortical carcinoma (functional and non-functional)
Disseminated testicular tumours; hypercalcaemia and hypercalciuria of malignancy. Discontinued in 2000
The publication year on key paper records.
Burnet FM. Progress in experimental tumor research.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Sarcomas (soft tissue, bone, GIST)
Osteosarcoma
Epithelioid sarcoma. Named for its resemblance to carcinoma and granuloma.
Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)
Secondary and therapy-related acute myeloid leukaemia
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Philadelphia, PA